Brief: Sanofi: Rilzabrutinib Earns Orphan Drug Designation In Japan For Igg4-Related Disease
02/03/2026 06:03
March 2 (Reuters) - Sanofi SA SASY.PA: SANOFI: RILZABRUTINIB EARNS ORPHAN DRUG DESIGNATION IN JAPAN FOR IGG4-RELATED DISEASE DESIGNATION BASED ON POSITIVE DATA FROM A PHASE 2 STUDY OF RILZABRUTINIB IN IGG4-RD Source text: nGNEm1RgM Further company coverage: SASY.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))
Recent news on Sanofi SA
See all newsFDA approves expanded use of Sanofi's type 1 diabetes drug (updated)
Brief: FDA Approves Tzield For Pediatric Stage 3 Type I Diabetes
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
European shares steady as investors weigh US-Iran flare-up (updated)
European shares steady as investors cling to Mideast peace hopes